Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy
|ClinicalTrials.gov Identifier: NCT00508703|
Recruitment Status : Completed
First Posted : July 30, 2007
Last Update Posted : September 12, 2017
|Condition or disease||Intervention/treatment|
|Uterine Cancer Cervical Cancer Endometrial Cancer||Radiation: Intensity Modulated Radiotherapy (IMRT) Procedure: CT Scan|
The standard radiotherapy technique for delivering radiation therapy to the pelvis following a hysterectomy involves a technique which also causes a large amount of normal tissue to receive radiation. This can cause both early and late side effects, which may be severe. The new technique of intensity modulated radiotherapy (IMRT) has been used to help spare normal tissue, especially tissue of the small bowel. This is an advanced new technology that delivers the high-dose of radiation to the target area but avoids the normal tissue. Using CT scans, the target is outlined by the doctors before treatment. However, sometimes organs in the pelvis move throughout the course of treatment. Using CT scans during treatment and re-outlining the target may help to deliver more radiation to the cancer tissues and less to the surrounding normal areas.
During the study, you will have additional CT scans that will be performed on a special scanner in the radiation treatment room. You also will have additional CT scans twice a week during the 5 weeks of radiation treatment. The first 12 participants enrolled will receive the standard radiation therapy taking into account the maximum possible movements of the bladder. No adjustments will be made according to the results of the additional CT scans. The next 12 participants may have their radiation therapy adjusted according to the CT scans in an effort to target less of the normal tissue without missing cancer tissue. To reduce movement of your bladder due to different amounts of fluid in your bladder, you will be asked to drink 3 glasses of water before treatment and to come for treatment with a full bladder.
The volumes of your bladder and rectum will also be studied, and any side effects of the treatment will be recorded. You will be asked to fill out a short questionnaire about the side effects of your treatment 3 times per week during treatment. It should take around 5 minutes to complete the questionnaire.
Patients will be followed for at least 2 years. (Every 3 months for 1 year and 4 months for second year according to usual clinic practice.)
This is an investigational study. IMRT radiation therapy is an approved method of treating some types of cancer. However, adjusting the radiation treatment according to the movement of the internal organs is investigational. Initial CT scans for treatment planning are part of standard treatment. Up to 24 participants will take part in this study. All will be enrolled at M. D. Anderson.
|Study Type :||Observational|
|Actual Enrollment :||24 participants|
|Official Title:||Pilot Study of Intensity Modulated Radiotherapy (IMRT) to Pelvis Post-Hysterectomy With Analysis of Clinical Target Volume Motion and Relation to Position and Volume of Bladder and Rectum During Course of Radiotherapy for Use in Optimization of Margin Size|
|Actual Study Start Date :||March 5, 2003|
|Actual Primary Completion Date :||September 8, 2017|
|Actual Study Completion Date :||September 8, 2017|
|CT Scan + IMRT Radiation Therapy||
Radiation: Intensity Modulated Radiotherapy (IMRT)
Dose of 45GyProcedure: CT Scan
CT Scans: Twice a week during the 5 weeks of radiation treatment.
Other Name: Computed Tomography
- Maximum variations in position of the vagina and lymph node regions caused by bladder filling and emptying [ Time Frame: 2 Years (every 3 months for first year and 4 months for second year) ]
- Day-to-day variations in position of vaginal vault and pelvic lymph node regions [ Time Frame: During a 5-week course of intensity modulated pelvic radiation therapy ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00508703
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Patricia J. Eifel, MD||M.D. Anderson Cancer Center|